Skip to content

Light at Night Study

Light at Night Study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04251234
Acronym
LAN
Enrollment
2
Registered
2020-01-31
Start date
2020-10-15
Completion date
2021-08-04
Last updated
2021-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder, Light Sensitivity

Keywords

Circadian, Light Intensity

Brief summary

The purpose of this mechanistic study is to examine light sensitivity (melatonin suppression) in people with bipolar depression I, and compare it to healthy controls. This is not a treatment study.

Detailed description

The bipolar disorder I and healthy control arms are recruited from the existing Heinz C. Prechter Bipolar Research Program at the University of Michigan.

Interventions

OTHERLight intensity, ~30 lux

\ 30 lux compared to very dim light baseline condition \<1 lux

OTHERBaseline light intensity, <1 lux

Very dim light condition

Sponsors

University of Michigan
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Masking description

There is no masking. The dim light (\<1 lux) condition is first, followed by the room light (\ 30 lux) condition. Participants are aware of this condition order.

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* BMI 18-30 kg/m2 * Appropriate sleep schedules according to study staff. Sleep schedule is self-reported and confirmed through a sleep diary * Healthy eyes as ascertained by eye exam at University of Michigan Kellogg Eye Center * Willing and able to maintain stable sleep schedule during study. * Participants will be breathalyzed and undergo urine drugs screens at every lab visit * Acknowledge and understand that participants cannot drive themselves home after certain lab visits. Note that the research team will provide a travel stipend of $10 per visit to offset potential rideshare/taxi costs

Exclusion criteria

* Color blindness

Design outcomes

Primary

MeasureTime frameDescription
Melatonin levelsUp to approximately 6 weeksMelatonin will be reported as an average percentage of suppression in the \ 30 lux condition as compared to \<1 lux

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026